Abstract:Background: Epigenetic silencing is a common mechanism to inactivate tumor suppressor genes during carcinogenesis. Enhancer of Zeste 2 (EZH2) is the histone methyltransferase subunit in polycomb repressive complex 2 which mediates transcriptional repression through histone methylation. EZH2 overexpression has been linked to aggressive phenotypes of certain cancers. However, the mechanism that EZH2 played in promoting malignancy in non-small cell lung cancer (NSCLC) remains unclear. In addition, the correlation of EZH2 overexpression and the prognosis of NSCLC patients in non-Asian cohort need to be determined.Methodology/Principal Findings: Up-regulation of EZH2 was found in NSCLC cells compared with normal human bronchial epithelial cells by western blot assay. Upon EZH2 knockdown using small interfering RNA (siRNA), the proliferation, anchorage-independent growth and invasion of NSCLC cells were remarkably suppressed with profound induction of G1 arrest. Furthermore, the expression of cyclin D1 was notably reduced whereas p15(INK4B), p21(Waf1/Cip1) and p27(Kip1) were increased in NSCLC cells after EZH2-siRNA delivery. To determine whether EZH2 expression contributes to disease progression in patients with NSCLC, Taqman quantitative real-time RT-PCR was used to measure the expression of EZH2 in paired tumor and normal samples. Univariate analysis revealed that patients with NSCLC whose tumors had a higher EZH2 expression had significantly inferior overall, disease-specific, and disease-free survivals compared to those whose tumors expressed lower EZH2 (P = 0.005, P = 0.001 and P = 0.003, respectively). In multivariate analysis, EZH2 expression was an independent predictor of disease-free survival (hazard ratio = 0.450, 95% CI: 0.270 to 0.750, P = 0.002).Conclusions/Significance: Our results demonstrate that EZH2 overexpression is critical for NSCLC progression. EZH2 mRNA levels may serve as a prognostic predictor for patients with NSCLC.

EMX2 is epigenetically silenced and suppresses growth in human lung cancer

EMX2 is Epigenetically Silenced and Suppresses Epithelial‑mesenchymal Transition in Human Esophageal Adenocarcinoma

Empty Spiracles Homeobox 2 (EMX2) Inhibits the Invasion and Tumorigenesis in Colorectal Cancer Cells.

CDX2 Serves As a Wnt Signaling Inhibitor and is Frequently Methylated in Lung Cancer

Silencing Sox2 Induced Mesenchymal-Epithelial Transition And Its Expression Predicts Liver And Lymph Node Metastasis Of Crc Patients

The Polycomb Group Protein Ezh2 Inhibits Lung Cancer Cell Growth by Repressing the Transcription Factor Nrf2

EMX2 is Downregulated in Endometrial Cancer and Correlated with Tumor Progression.

EMX2 gene expression predicts liver metastasis and survival in colorectal cancer

EMX2 is a Predictive Marker for Adjuvant Chemotherapy in Lung Squamous Cell Carcinomas.

CBX2 and EZH2 Cooperatively Promote the Growth and Metastasis of Lung Adenocarcinoma

EMX2 inhibits clear cell renal cell carcinoma progress via modulating Akt/FOXO3a pathway

Adenoviral Delivery Of The Emx2 Gene Suppresses Growth In Human Gastric Cancer

EFEMP2 Suppresses the Invasion of Lung Cancer Cells by Inhibiting Epithelial-Mesenchymal Transition (EMT) and Down-Regulating MMPs

Silencing Of Brain-Expressed X-Linked 2 (Bex2) Promotes Colorectal Cancer Metastasis Through The Hedgehog Signaling Pathway

The function of lncRNA EMX2OS/miR-653-5p and its regulatory mechanism in lung adenocarcinoma

Regulation of sarcomagenesis by the empty spiracles homeobox genes EMX1 and EMX2

Epigenetic Silencing of TMEM176A Activates ERK Signaling in Human Lung Cancer

SOX2 Gene Regulates the Transcriptional Network of Oncogenes and Affects Tumorigenesis of Human Lung Cancer Cells.

The Expression and Significance of the Enhancer of Zeste Homolog 2 in Lung Adenocarcinoma.

Identification ofLBX2as a novel causal gene of lung adenocarcinoma

Ezh2 Promotes Malignant Behaviors Via Cell Cycle Dysregulation And Its Mrna Level Associates With Prognosis Of Patient With Non-Small Cell Lung Cancer